Hussman Strategic Advisors’s Vanda Pharmaceuticals VNDA Stock Holding History

Hussman Strategic Advisors’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-156,000	Closed	-$674K	–	299
2023 Q3	$674K	Hold	156,000	–	–	0.13%	229
2023 Q2	$1.03M	Hold	156,000	–	–	0.19%	213
2023 Q1	$1.06M	Hold	156,000	–	–	0.17%	212
2022 Q4	$1.15M	Hold	156,000	–	–	0.19%	188
2022 Q3	$1.54M	Hold	156,000	–	–	0.27%	156
2022 Q2	$1.7M	Hold	156,000	–	–	0.29%	128
2022 Q1	$1.76M	Hold	156,000	–	–	0.34%	115
2021 Q4	$2.45M	Buy	156,000 +32,000	+26%	+$558K	0.54%	60
2021 Q3	$2.13M	Buy	124,000 +31,000	+33%	+$543K	0.47%	84
2021 Q2	$2M	Buy	93,000 +21,000	+29%	+$376K	0.41%	86
2021 Q1	$1.08M	Buy	72,000 +21,000	+41%	+$340K	0.22%	177
2020 Q4	$670K	Buy	51,000 +16,000	+46%	+$193K	0.18%	201
2020 Q3	$338K	Buy	+35,000	New	+$374K	0.09%	236

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Hussman Strategic Advisors's VNDA Position: Q4 2023 in Review

Hussman Strategic Advisors sold out of Vanda Pharmaceuticals (VNDA) in Q4 2023, closing a stake of 156,000 shares — an estimated $674K sold.

Hussman Strategic Advisors first reported a position in VNDA in Q3 2020 and held it in 13 quarters. The position peaked at $2.45M in Q4 2021. 157 funds tracked by Wall St. Rank hold VNDA as of Q4 2023.

Hussman Strategic Advisors reported no remaining Vanda Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Hussman Strategic Advisors sold 156,000 Vanda Pharmaceuticals shares in Q4 2023, an estimated $674K.
Hussman Strategic Advisors first reported a position in Vanda Pharmaceuticals in Q3 2020 and held it in 13 quarters.
Hussman Strategic Advisors's Vanda Pharmaceuticals position peaked at $2.45M in Q4 2021.
157 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2023.

Based on Hussman Strategic Advisors's 13F filing for Q4 2023, filed 1 Feb 2024.